- $1.22bn
- $1.17bn
- $30.91m
Brief: Verastem Oncology Announces Proposed Public Offering Of Common Stock
Verastem Oncology Q3 revenue hits $11.2 mln, net loss widens
Brief: Verastem Oncology Announces Encouraging Preliminary Data From Ongoing Phase 1/2A Dose Escalation Trial Of Versus-7375, An Oral Kras G12d (On/Off) Inhibitor, In Patients With Kras G12d Mutant Solid Tumors
Brief: Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Brief: Verastem Inc Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Verastem Inc reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Verastem Oncology Q2 net loss widens
Verastem Inc expected to post a loss of 74 cents a share - Earnings Preview
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule
Brief: Verastem Oncology Announces First Patient Dosed With VS-7375, An Oral KRAS G12D Inhibitor, In US Phase 1/2A Trial In KRAS G12D Advanced Solid Tumors
Brief: Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
Brief: Verastem Q1 Basic EPS USD -0.96
Verastem climbs on FDA approval of ovarian cancer therapy
Pack Expected To Be Available For Adult Patients In U.S. In One Week
US FDA approves Verastem's cancer therapy (updated)
U.S. FDA approves Verastem's cancer therapy
Brief: FDA Grants Accelerated Approval To Combination Of Avutometinib And Defactinib For Kras-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Inc expected to post a loss of 71 cents a share - Earnings Preview